SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D/A
Amendment No.2
Under the Securities Exchange Act of 1934
ELITE PHARMACEUTICALS, INC.
--------------------------------------------------------------------------------
(Name of Issuer)
Common Stock, Par Value $0.01 Per Share
--------------------------------------------------------------------------------
(Title of Class of Securities)
28659T200
--------------------------------------------------------------------------------
(CUSIP Number)
Edson Moore Healthcare Ventures, Inc.
John A. Moore
Hilary Edson
101 Brookmeadow Road
Wilmington, Delaware 19807
(302) 994-3083
--------------------------------------------------------------------------------
(Name, Address and Telephone Number of Person Authorized to
Receive Notices and Communications)
October 17, 2002
--------------------------------------------------------------------------------
(Date of Event which Requires Filing of this Statement) (* See Item 3)
If the filing person has previously filed a statement on Schedule 13G to report
the acquisition which is the subject of this Schedule 13D, and is filing this
schedule because of ss. 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the
following box. [ ]
Note: Schedules filed in paper format shall include a signed original and five
copies of the schedule, including all exhibits. See ss. 240.13d-7(b) for other
parties to whom copies are to be sent.
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter
disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
SCHEDULE 13D
--------------------------------------------------------------------------------
CUSIP NO. 28659T200 PAGE 2 OF 8 PAGES
--------------------------------------------------------------------------------
1 NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
Edson Moore Healthcare Ventures, Inc. 04-3694908
--------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (A) [ ]
(SEE INSTRUCTIONS) (B) [X]
--------------------------------------------------------------------------------
3 SEC USE ONLY
--------------------------------------------------------------------------------
4 SOURCE OF FUNDS (SEE INSTRUCTIONS)
WC
--------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS
REQUIRED PURSUANT TO ITEMS 2(D) OR 2(E) [ ]
--------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
--------------------------------------------------------------------------------
7 SOLE VOTING POWER
NUMBER OF SHARES BENEFICIALLY -864,218-
OWNED BY EACH REPORTING 8 SHARED VOTING POWER
PERSON WITH -0-
9 SOLE DISPOSITIVE POWER
-864,218-
10 SHARED DISPOSITIVE POWER
-0-
--------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
864,218
--------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN [ ]
SHARES (SEE INSTRUCTIONS)
--------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
8.12%
--------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
CO
SCHEDULE 13D
--------------------------------------------------------------------------------
CUSIP NO. 28659T200 PAGE 3 OF 8 PAGES
--------------------------------------------------------------------------------
1 NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
John A. Moore
--------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (A) [ ]
(SEE INSTRUCTIONS) (B) [X]
--------------------------------------------------------------------------------
3 SEC USE ONLY
--------------------------------------------------------------------------------
4 SOURCE OF FUNDS (SEE INSTRUCTIONS)
OO
--------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS
REQUIRED PURSUANT TO ITEMS 2(D) OR 2(E) [ ]
--------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
United States
--------------------------------------------------------------------------------
7 SOLE VOTING POWER
NUMBER OF SHARES BENEFICIALLY -0-
OWNED BY EACH REPORTING 8 SHARED VOTING POWER
PERSON WITH -864,218-
9 SOLE DISPOSITIVE POWER
-0-
10 SHARED DISPOSITIVE POWER
-864,218-
--------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
864,218
--------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN [ ]
SHARES (SEE INSTRUCTIONS)
--------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
8.12%
--------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
IN
SCHEDULE 13D
CUSIP NO. 28659T200 PAGE 4 OF 8 PAGES
--------------------------------------------------------------------------------
1 NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
Hilary Edson
--------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (A) [ ]
(SEE INSTRUCTIONS) (B) [X]
--------------------------------------------------------------------------------
3 SEC USE ONLY
--------------------------------------------------------------------------------
4 SOURCE OF FUNDS (SEE INSTRUCTIONS)
OO
--------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS
REQUIRED PURSUANT TO ITEMS 2(D) OR 2(E) [ ]
--------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
United States
--------------------------------------------------------------------------------
7 SOLE VOTING POWER
NUMBER OF SHARES BENEFICIALLY -0-
OWNED BY EACH REPORTING 8 SHARED VOTING POWER
PERSON WITH -864,218-
9 SOLE DISPOSITIVE POWER
-0-
10 SHARED DISPOSITIVE POWER
-864,218-
--------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
864,218
--------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN [ ]
SHARES (SEE INSTRUCTIONS)
--------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
8.12%
--------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
IN
This Amendment No.2 to Schedule 13D amends and restates the Schedule 13D
initially filed with the Securities and Exchange Commission (the "SEC"), on
January 6, 2003 (the "Initial Filing"), as amended by Amendment No. 1 thereto
filed with the SEC on February 13, 2003 (as amended, the "Statement"). The
Initial Filing was filed using an incorrect CIK identifier code; this Statement
is being filed in correction thereof.
ITEM 1. SECURITY AND ISSUER.
This Statement relates to the common stock, $0.01 par value per share (the
"Elite Common Stock"), of Elite Pharmaceuticals, Inc., a Delaware corporation
(the "Issuer"). The principal executive offices of the Issuer are located at 165
Ludlow Avenue, Northvale, New Jersey 17647.
ITEM 2. IDENTITY AND BACKGROUND.
(a) This Schedule 13D is jointly filed by Edson Moore Healthcare Ventures, Inc.,
formerly Edson Moore Corp., a Delaware corporation ("EMC"), John A. Moore and
Hilary Edson (each individually a "Reporting Person" and, collectively, the
"Reporting Persons"). Mr. Moore and Ms. Edson each own 50% of the outstanding
capital stock of EMC.
Information contained herein with respect to each Reporting Person is given
solely by such Reporting Person, and no other Reporting Person has
responsibility for the accuracy or completeness of information supplied by such
other Reporting Person.
(b) The business address for all Reporting Persons is 101 Brookmeadow Road,
Wilmington, Delaware 19807.
(c) Mr. Moore was elected to the board of directors of the Issuer at the annual
shareholders meeting of the Issuer held on December 12, 2002. Mr. Moore is the
president, chief executive officer and director of EMC. Ms. Edson is the
secretary and director of EMC.
(d) During the last five years, none of the Reporting Persons has been convicted
in a criminal proceeding (excluding traffic violations or similar misdemeanors).
(e) During the last five years, none of the Reporting Persons has been a party
to a civil proceeding of a judicial or administrative body of competent
jurisdiction and as a result of such proceeding was or is subject to a judgment,
decree or final order enjoining future violations of, or prohibiting or
mandating activities subject to, Federal or state securities laws or finding any
violation with respect to such laws.
(f) EMC is a Delaware corporation. Each of Mr. Moore and Ms. Edson are United
States citizens.
ITEM 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION.
On September 27, 2002, EMC acquired (i)12,015 shares of Series A Preferred Stock
of Elite Labs (which were exchangeable for shares of Elite Common Stock on or
after October 17, 2002), (ii) the right to receive all additional shares of
Series A Preferred Stock of Elite Laboratories, Inc., a wholly-owned subsidiary
of the Issuer ("Elite Labs") issuable as accrued and unpaid payment-in-kind
dividends upon the 12,015 shares of Series A Preferred Stock of Elite Labs
described in clause (i) above, and (iii) the warrant to purchase 100,000 shares
of Elite Common Stock of the Issuer (collectively, the "Acquired Securities")
from Shelly Bay Holdings, Ltd., a Bermuda exempted limited liability company,
for an aggregate purchase price of $485,000.
On October 17, 2002, pursuant to a letter agreement between EMC and the Issuer
(see Item 6 below), EMC agreed to exchange 12,015 shares of Series A Preferred
Stock, par value $1.00 per share, of Elite Labs for 714,222 shares of Elite
Common Stock.
On November 5, 2002, pursuant to a letter agreement between EMC and the Issuer
(see Item 6 below), EMC agreed to exchange 900 shares of Series A Preferred
Stock of Elite Labs which were issued by Elite Labs as paid-in-kind dividends
accrued through June 29, 2002, on 12,015 shares of Series A Preferred Stock
(described in the previous sentence) for 49,996 shares of Elite Common Stock.
The 864,218 shares of Elite Common Stock beneficially owned by the Reporting
Persons consist of (i) 714,222 shares of Elite Common Stock issued to EMC upon
the exchange of the 12,015 shares of Series A Preferred Stock (referred to in
the previous paragraph), (ii) 49,996 shares of Elite Common Stock issued to EMC
upon the exchange of the 900 shares of Series A Preferred Stock (referred to in
the previous paragraph) and (iii) 100,000 shares of Elite Common Stock issuable
upon the exercise by EMC of a warrant to purchase 100,000 shares of Elite Common
Stock (exercisable through October 17, 2005) at an exercise price of $18.00 per
share.
ITEM 4. PURPOSE OF TRANSACTION.
The Reporting Persons purchased the Shares for investment purposes. Each
Reporting Person presently considers the Elite Common Stock an attractive
investment and intends to review its investment on an ongoing basis. Such
continuing review may result in a Reporting Person acquiring additional shares
of Elite Common Stock in the open-market or in privately negotiated
transactions, maintaining its holdings at current levels or selling all or a
portion of its holdings in the open-market or in privately negotiated
transactions. Any such actions the Reporting Persons undertake will be dependent
upon, among other things, the availability of shares of Elite Common Stock for
purchase and the price levels of such shares; general market and economic
conditions; on-going evaluation of the Issuer's business, financial condition,
operations and prospects; the relative attractiveness of alternative business
and investment opportunities; the availability of funds for the purchase of
additional shares of Elite Common Stock; the actions of the management and Board
of Directors of the Issuer; and other future developments. Although the
foregoing reflects activities presently contemplated by the Reporting Persons
with respect to the Issuer, the foregoing is subject to change at any time.
Except as set forth above, the Reporting Persons have no present plans or
intentions which would result in or relate to any of the transactions described
in subparagraphs (a) through (j) of Item 4 of Schedule 13D, except that with
respect to subparagraph (d), Mr. John Moore has proposed that Mr. Atul Mehta,
Chairman of the Board of Directors of the Issuer and President and Chief
Executive Officer of the Issuer, surrender his position as Chairman of the Board
of Directors and that Mr. Moore be appointed by the Board of Directors as
Chairman of the Board of Directors. Mr. Moore may propose or suggest other
changes in the management and the present Board of Directors of the Issuer,
including an increase in the number of directors, although no representation is
made that any further change will be proposed or effected.
ITEM 5. INTEREST IN THE SECURITIES OF THE COMPANY.
(a) As of December 16, 2002 and the date of this Statement (i) Mr. Moore
beneficially owns 864,218 shares of Elite Common Stock, which represent
approximately 8.12% of Elite Common Stock outstanding, (ii) Ms. Edson
beneficially owns 864,218 shares of Elite Common Stock, which represent
approximately 8.12% of Elite Common Stock outstanding and (iii) EMC beneficially
owns 864,218 shares of Elite Common Stock, which represent approximately 8.12%
of Elite Common Stock outstanding (based on 9,780,205 shares of Elite Common
Stock of the Issuer reported as being outstanding in the Issuer's Form 10-Q
filed September 30, 2002). For purposes of disclosing the number of shares
beneficially owned by each of the Reporting Persons, Mr. Moore and Ms. Edson are
deemed to beneficially own all shares of Elite Common Stock that are
beneficially owned by EMC.
(b) Each Reporting Person has (i) the sole power to vote or direct the vote of
the 864,218 shares of Elite Common Stock held by EMC and (ii) the sole power to
dispose of or to direct the disposition of such 864,218 shares of Elite Common
Stock; provided that, Mr. Moore and Ms. Edson share with each other their voting
and disposition power through their 50%/50% ownership of EMC.
(c) Except for the acquisition of the shares described herein, to the best
knowledge and belief of the undersigned, no transactions involving the Elite
Common Stock have been effected during the past 60 days by the Reporting Persons
or by their directors, executive officers or controlling persons.
(d) n/a
(e) n/a
ITEM 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO
SECURITIES OF THE COMPANY.
1. Letter Agreement, dated October 17, 2002, between EMC and the
Issuer.
2. Letter Agreement, dated November 5, 2002, between EMC and the
Issuer.
ITEM 7. MATERIAL TO BE FILED AS EXHIBITS.
1. Joint Filing Agreement, dated December 16, 2002, among Edson Moore
Corp., a Delaware corporation, John A. Moore and Hilary Edson.
2. Letter Agreement, dated October 17, 2002, between EMC and the
Issuer.
3. Letter Agreement, dated November 5, 2002, between EMC and the
Issuer.
SIGNATURES
After reasonable inquiry and to the best of my knowledge and belief,
the undersigned certifies that the information set forth in this statement is
true, complete and correct.
Date: February 14, 2003
Edson Moore Corp.
By: /s/ John A. Moore
--------------------------------
Name: John A. Moore
Title: Chief Executive Officer
/s/ John A. Moore
-----------------------------
John A. Moore
/s/ Hilary Edson
-----------------------------
Hilary Edson